Drugs / HLX29
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07776132 | Nov 2026 → Jan 2027 expected | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07776132 ↗ |
| Route | Intravenous | “subjects will receive a single intravenous dose of HLX29” NCT07776132 ↗ |